Rapid Novor Opens Research Lab In Kitchener To Develop The Next-Generation Protein Sequencing Technology
KITCHENER, Ontario, July 19, 2017 /PRNewswire-iReach/ — Rapid Novor Inc, the world leader in next-generation protein sequencing, today announces that after six months of planning, setup and testing, its first proteomics grade mass spectrometry lab is now fully in operation. This ~$1M investment represents the company’s commitment to developing the next-generation protein sequencing technology.
The opening of the new lab lays out the foundation for Rapid Novor’s future innovation. With the direct access and control of this high resolution, high mass accuracy mass spectrometer, the company is able to complete customer projects more efficiently and be more competitive in the marketplace. More importantly, the lab enables an accelerated innovation timeline and is critical for the company to maintain the leader position in this technology direction.
“Mass spectrometry based, high-throughput protein sequencing is ground breaking.” said Dr. Bin Ma, President and Chief Scientist of Rapid Novor. “This is analogous to the invention of genome sequencing technology, which enabled a whole industry and fundamentally changed the way people conduct biology and health research. Now we are at a similar situation that high-throughput protein sequencing becomes possible. With the opening of our own lab, we are well-positioned to make this change to the scientific community.”
About Rapid Novor Inc
Rapid Novor Inc is a privately held biotechnology company that develops the next-generation protein sequencing technologies and solutions. Specializing in the field of mass spectrometry-based proteomics, the company has developed the technology to directly sequence the antibody proteins without the needs to access the cell line. The company’s mission is to advance life science for better human health with next-generation protein sequencing. The company is headquartered in Kitchener, Ontario, Canada. For more information, visit www.rapidnovor.com.
Media Contact:Mingjie Xie, Rapid Novor Inc, +1 (519) 593-2260, mxie@rapidnovor.com
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics